Neuropharmacology
May 13, 2022
Cynthia E. Ortiz, Haley Maria Dourron, Noah W Sweat et al.
26 citations
Psilocybin-facilitated psychotherapy may be effective across many mental health conditions, but vulnerable populations, who carry a disproportionate mental health burden, have been largely excluded from clinical research. This report highlights the need to include these groups in studies, considering their problematic historical context and differential experiences with psychedelics. It offers actionable recommendations for future research, such as improved recruitment strategies, careful communication of subjective effects, building therapeutic alliance, multicultural competence, and flexible study designs. The authors call for expanded and improved research in this rapidly advancing field.
Psychedelic Med (New Rochelle)
December 13, 2023
Nicholas A. Carlisle, Haley Maria Dourron, Sarah Maccarthy et al.
12 citations
Chronic shame, often stemming from internalized stigma, disproportionately affects sexual and gender minority (SGM) adults and undermines mental health. This theoretical and philosophical paper argues that psychedelic-assisted therapy holds unique potential to reduce such shame by disrupting rigid self-narratives and fostering self-compassion. The authors suggest that the pharmacological and contextual features of psychedelic experiences—particularly enhanced emotional openness and mystical-type experiences—may directly target shame-related neural and psychological processes. They propose that psychedelic therapy could offer SGM individuals a reparative pathway toward healing and psychological wellness, distinct from conventional treatments. The paper calls for further empirical investigation into psychedelics as a tailored intervention for chronic shame in this population.
Scientific Reports
January 28, 2026
Nicholas A. Carlisle, Otto Simonsson, Sarah Maccarthy et al.
About one in five people who have used psychedelics report at least one major life change they attribute to the experience. Common changes involve relationships (6.9%), diet and exercise (6.2%), quitting alcohol, tobacco, or other substances (5.5%), and religious beliefs (5.5%). In a larger, more diverse sample, higher religiosity, younger age, and greater lifetime psychedelic use were strongly associated with reporting such changes. The findings suggest that major life changes after psychedelic use are not rare and may vary by demographic factors, but more longitudinal research is needed to understand their persistence, valence, and health impact.